Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial

American Heart Journal

Volumn 152, Issue 1, 2006, Pages 157-163

  Exaire, J Emilio ^a   Butman, Samuel M ^b   Ebrahimi, Ramin ^c   Kleiman, Neal S ^d   Harrington, Robert A ^e   Schweiger, Marc J ^f   Bittl, John A ^g   Wolski, Kathy ^a   Topol, Eric J ^a   Lincoff, A Michael ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f BAYSTATE MEDICAL CENTER   (United States)

^g Ocala Heart Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PLACEBO;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOUBLE BLIND PROCEDURE; DRUG USE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; TREATMENT PLANNING; VALIDATION STUDY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTITHROMBINS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HIRUDINS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; RISK FACTORS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 33745665813     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.09.004     Document Type: Article

References (24)

1. Cannon C.P., Maraganore J.M., Loscalzo J., et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 71 (1993) 778-782
2. Fuchs J., and Cannon C.P. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 92 (1995) 727-733
3. Bittl J.A., Strony J., Brinker J.A., et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 333 (1995) 764-769
4. Topol E.J., Bonan R., Jewitt D., et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 87 (1993) 1622-1629
5. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
6. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 8 Pt 2 (1997) 757-763
7. Ellis S.G., Roubin G.S., King III S.B., et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 77 (1988) 372-379
8. Ellis S.G., Topol E.J., Gallison L., et al. Predictors of success for coronary angioplasty performed for acute myocardial infarction. J Am Coll Cardiol 12 (1988) 1407-1415
9. Ellis S.G., Vandormael M.G., Cowley M.J., et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 82 (1990) 1193-1202
10. Ellis S.G., and Topol E.J. Results of percutaneous transluminal coronary angioplasty of high-risk angulated stenoses. Am J Cardiol 66 (1990) 932-937
11. Ellis S.G. Coronary lesions at increased risk. Am Heart J 130 3 Pt 2 (1995) 643-646
12. Ellis S.G., Guetta V., Miller D., et al. Relation between lesion characteristics and risk with percutaneous intervention in the stent and glycoprotein IIb/IIIa era: an analysis of results from 10,907 lesions and proposal for new classification scheme. Circulation 100 (1999) 1971-1976
13. Ross M.J., Herrmann H.C., Moliterno D.J., et al. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. J Am Coll Cardiol 42 (2003) 981-988
14. Moliterno D.J., Califf R.M., Aguirre F.V., et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 75 (1995) 559-562
15. Tcheng J.E. Dosing and administration of ReoPro (c7E3 Fab). J Invasive Cardiol 6 Suppl A (1994) 29A-33A [discussion 51A-54A]
16. Popma J.J., and Satler L.F. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC trial results. J Invasive Cardiol 6 Suppl A (1994) 19A-28A [discussion 45A-50A]
17. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349 (1997) 1429-1435
18. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 (1997) 1689-1696
19. Lincoff A.M., Califf R.M., Anderson K.M., et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 30 (1997) 149-156
20. Topol E.J., Ferguson J.J., Weisman H.F., et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 278 (1997) 479-484
21. Ellis S.G., Lincoff A.M., Miller D., et al. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA to Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. J Am Coll Cardiol 32 (1998) 1619-1623
22. Fox K.A., Goodman S.G., Anderson Jr. F.A., et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1414-1424
23. Lincoff A.M., Bittl J.A., Kleiman N.S., et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 93 (2004) 1092-1096
24. Kastrati A., Mehilli J., Schuhlen H., et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 (2004) 232-238